Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Director · See Remarks | January 02, 2025 | January 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Werewolf Therapeutics, Inc.
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-12-31 | Direct | 592,690 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 592,690 · Balance 592,690 F1: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2034-12-31 | Direct | 185,652 |
Reported balance
After 2025-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-02 · Grant · Acquired 185,652 · Balance 185,652 |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 6, 2025 17:41 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 185,652 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000950170-25-002336 · ownership.xml · derivative · entry 2 HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,652 Underlying: Common Stock · 185,652 shares Expires 2034-12-31 Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 17:41 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 592,690 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000950170-25-002336 · ownership.xml · derivative · entry 1 HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 592,690 Underlying: Common Stock · 592,690 shares Expires 2034-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2025 with a Vesting Commencement Date of January 1, 2025. The shares underlying the option vest in equal monthly installments over four years, with the initial vesting to commence on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2029. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:26 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 435,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0000950170-24-001894 · ownership.xml · derivative · entry 1 HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,000 Underlying: Common Stock · 435,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The option was granted on January 2, 2024 with a Vesting Commencement Date of January 1, 2024. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2028. Read SEC document |
| January 03, 2023 Filed Jan 9, 2023 21:38 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 295,500 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0000899243-23-001413 · doc4.xml · derivative · entry 1 HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,500 Underlying: Common Stock · 295,500 shares Expires 2032-12-31 F1 · derivative.exercise_date: The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027. Read SEC document |
| January 06, 2022 Filed Jan 18, 2022 18:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 215,888 | $0.00 Strike: $11.55 | $0.00 |
DisclosureSEC source: 0000899243-22-002202 · doc4.xml · derivative · entry 1 HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,888 Underlying: Common Stock · 215,888 shares Expires 2032-01-05 F1 · derivative.exercise_date: The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026. Read SEC document |
| April 30, 2021 Filed May 4, 2021 16:04 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 155,416 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018089 · doc4.xml · derivative · entry 2 HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,416 Underlying: Common Stock · 155,416 shares Expires 2031-04-29 F2 · derivative.exercise_date: The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025. Read SEC document |
| December 08, 2020 Filed May 4, 2021 16:04 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 727,377 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0000899243-21-018089 · doc4.xml · derivative · entry 1 HICKLIN DANIEL J · CIK 0001260929 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,377 Underlying: Common Stock · 727,377 shares Expires 2030-12-07 F1 · derivative.exercise_date: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.